Jupai Holdings Limited (JP) Reaches $20.10 After 4.00% Up Move; 9 Analysts Are Bullish Teva Pharmaceutical Industries Limited (TEVA) Last Week

February 15, 2018 - By reb123z

The stock of Jupai Holdings Limited (NYSE:JP) is a huge mover today! The stock increased 9.30% or $1.71 during the last trading session, reaching $20.1. About 137,293 shares traded. Jupai Holdings Limited (NYSE:JP) has declined 9.45% since February 15, 2017 and is downtrending. It has underperformed by 26.15% the S&P500.The move comes after 7 months positive chart setup for the $663.86 million company. It was reported on Feb, 15 by Barchart.com. We have $20.90 PT which if reached, will make NYSE:JP worth $26.55M more.

Among 35 analysts covering Teva Pharma (NYSE:TEVA), 9 have Buy rating, 8 Sell and 18 Hold. Therefore 26% are positive. Teva Pharma had 145 analyst reports since July 21, 2015 according to SRatingsIntel. On Wednesday, January 4 the stock rating was maintained by Maxim Group with “Buy”. The rating was maintained by Morgan Stanley on Thursday, October 5 with “Underweight”. Oppenheimer maintained it with “Buy” rating and $4100 target in Friday, July 14 report. Jefferies downgraded Teva Pharmaceutical Industries Limited (NYSE:TEVA) on Wednesday, November 16 to “Hold” rating. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Market Perform” rating given on Friday, August 4 by Cowen & Co. Wells Fargo initiated the shares of TEVA in report on Friday, February 19 with “Outperform” rating. The firm earned “Sell” rating on Friday, January 26 by Leerink Swann. Mizuho maintained the stock with “Neutral” rating in Wednesday, November 16 report. The company was downgraded on Friday, February 9 by Gabelli. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Overweight” rating given on Monday, August 3 by JP Morgan. See Teva Pharmaceutical Industries Limited (NYSE:TEVA) latest ratings:

12/02/2018 Broker: BTIG Research Rating: Sell New Target: $17.0 Maintain
12/02/2018 Broker: Credit Suisse Old Rating: Neutral New Rating: Outperform Upgrade
09/02/2018 Broker: Leerink Swann Old Rating: Underweight New Rating: Underperform Old Target: $17 New Target: $16 Maintain
09/02/2018 Broker: Gabelli Rating: Hold Downgrade
09/02/2018 Broker: Deutsche Bank Old Rating: Hold New Rating: Hold Old Target: $20 New Target: $18 Maintain
09/02/2018 Broker: RBC Capital Markets Rating: Hold Upgrade
08/02/2018 Broker: Cowen & Co Rating: Hold New Target: $16.0 Maintain
09/02/2018 Broker: PiperJaffray Old Rating: Neutral New Rating: Underweight Downgrade
01/02/2018 Broker: BTIG Research Rating: Hold Maintain
31/01/2018 Broker: Guggenheim Rating: Hold Maintain

The stock increased 7.27% or $1.41 during the last trading session, reaching $20.74. About 29.20 million shares traded or 24.82% up from the average. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 41.70% since February 15, 2017 and is downtrending. It has underperformed by 58.40% the S&P500.

Teva Pharmaceutical Industries Limited develops, makes, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. The company has market cap of $21.07 billion. It operates through two divisions, Generic Medicines and Specialty Medicines. It currently has negative earnings. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Analysts await Jupai Holdings Limited (NYSE:JP) to report earnings on February, 27. They expect $0.43 EPS, up 48.28% or $0.14 from last year’s $0.29 per share. JP’s profit will be $14.20M for 11.69 P/E if the $0.43 EPS becomes a reality. After $0.52 actual EPS reported by Jupai Holdings Limited for the previous quarter, Wall Street now forecasts -17.31% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>